Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University has today been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

The Kennedy Trust logo

The scheme will fund 15 students a year for 5 years, 4 of whom will be in Oxford. The other successful Universities Birmingham, Manchester and Glasgow/Edinburgh. The scheme follows the successful launch this year of a BM DPhil educational training program in cancer studies funded by CRUK. Students will be hosted within the Medical Sciences Doctoral training program.

Professor Paul Bowness, Professor of Experimental Rheumatology who led the application, said: "Oxford is thrilled to join the Kennedy Trust MB PhD scheme. This scheme will provide a unique opportunity to educate a new generation of clinician scientists, harnessing Oxford's established research strengths. We are confident these doctors will lead research for the benefit of patients with musculoskeletal diseases many years to come."

Professor Sir Stephen Holgate, The Kennedy Trust's Chairman and MRC Professor of Immunopharmacology at the University of Southampton, said: "The MB PhD initiative combines two of the Kennedy Trust's key aims: investment into translational research and the support of early career scientists. We are delighted to build upon the fantastic programme established by the University of Oxford and we are confident that the Trust's MB PhD scheme will deliver the next generation of clinical academic leaders in musculoskeletal and inflammatory disease research.'"

More details of the Kennedy Trust announcement

How to apply for the Oxford Kennedy MB PhD (BM DPhil) Educational Training Program.

Similar stories

Fiona Powrie honoured by British Society for Immunology

Fiona Powrie was one of four researchers from the University of Oxford recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology.

The Kennedy Institute scoops sustainability award

A new roof extension was awarded the 2021 Green Award for Sustainability by the Oxford Preservation Trust alongside a Certificate in the New Building category.

Vaccination safety: generating accurate evidence is the clearest path to creating public trust

A new study shows that a vaccine surveillance method in observational data may generate high number of false positives

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

Single-cell ancestry vaccine research funded by the Chan Zuckerberg Initiative

The Chan Zuckerberg Initiative (CZI) has provided $2 million in funding to investigate how our ancestry and diversity influence the way that vaccines work in our cells.